Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma

Bibliography

• Rubin B, Fink J. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 2005;50(9):1191-7
   PubMedGoogle Scholar
• Mitchell J, Nagel M. Valved holding chambers (VHCs) for use with pressurized metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J 2007;16(4):207-14
   PubMedGoogle Scholar
• Woodcock A. CFCs and inhalers. Lancet 1994;344:182-3
   Web of Science ®Google Scholar
• The Montreal Protocol on Substances that Deplete the Ozone Layer, as adjusted and/or amended in London 1990, Copenhagen 1992, Vienna 1995, Montreal 1997, and Beijing 1999. Available from: www.unep.org/ozone/montreal-protocol/montreal-rotocol2000.shtml [Last accessed 18 September 2014]
   Google Scholar
• Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin Drug Deliv 2007;4(3):215-34
   PubMed Web of Science ®Google Scholar
• Price D, Roche N, Virchow JC, et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 2011;105:1457-66
   PubMed Web of Science ®Google Scholar
• Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005;50(3):367-82
   PubMedGoogle Scholar
• Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9(1):55-70
   PubMedGoogle Scholar
• Newman SP. Principles of metered-dose inhaler design. Respir Care 2005;50(9):1177-90
   PubMedGoogle Scholar
• Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001;14(2):197-208
   PubMedGoogle Scholar
• Versteeg HK, Hargrave G. Fundamentals and resilience of the original MDI actuator design. Proceedings of Respiratory Drug Delivery X; Boca Raton, FL, USA; 2006. p. 91-100
   Google Scholar
• Everard ML. Aerosol therapy past, present, and future: a clinician’s perspective. Respir Care 2000;45(6):769-76
   PubMedGoogle Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105(6):930-8
   PubMed Web of Science ®Google Scholar
• Price D, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting b2-agonist combinations in the treatment of asthma. Respir Med 2012;106(S1):S4-8
   Google Scholar
• The Global Initiative for Asthma. Revised 2014. Global Strategy for Asthma Management and Prevention. Available from: www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf [Last accessed 18 September 2014]
   Google Scholar
• Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundbäck B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroid with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8
   PubMed Web of Science ®Google Scholar
• Condemi JJ, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol study group. Ann Allergy Asthma Immunol 1999;82:383-9
   PubMed Web of Science ®Google Scholar
• Van Noord JA, Schreurs AJ, Mol SJ, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999;54:207-12
   PubMed Web of Science ®Google Scholar
• Murray JJ, Church NL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999;20:173-80
   PubMed Web of Science ®Google Scholar
• Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 mg twice daily in treating moderate to severe asthma. Respir Med 2000;94:715-23
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170(8):836-44
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005;27(4):393-406
   PubMed Web of Science ®Google Scholar
• Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006;28(1):73-85
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004;41(8):797-806
   PubMed Web of Science ®Google Scholar
• Nelson HS, Wolfe JD, Gross G, et al. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 2003;91(3):263-9
   PubMed Web of Science ®Google Scholar
• Cowie RL, Boulet LP, Keith PK, et al. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Clin Ther 2007;29(7):1390-402
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Dymek A, McAulay K, et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011;11:28
   PubMed Web of Science ®Google Scholar
• Maspero JF, Nolte H, Chérrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma 2010;47(10):1106-15
   PubMed Web of Science ®Google Scholar
• Sheth K, Wasserman RL, Lincourt WR, et al. Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: performance and patient satisfaction. Int J Clin Pract 2006;60(10):1218-24
   PubMed Web of Science ®Google Scholar
• Edin HM, Andersen LB, Schoaf L, et al. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. Ann Allergy Asthma Immunol 2009;102(4):323-7
   PubMed Web of Science ®Google Scholar
• Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001;95(2):136-46
   PubMed Web of Science ®Google Scholar
• You-Ning L, Humphries M, Du X, et al. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int J Clin Pract 2005;59(7):754-9
   PubMed Web of Science ®Google Scholar
• Van Noord JA, Lill H, Diaz TC, et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500μg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus™ in patients with moderate to severe asthma. Clin Drug Invest 2001;21(4):243-55
   Web of Science ®Google Scholar
• Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002;110:S322-8
   PubMedGoogle Scholar
• Castle W, Fuller R, Hall J, et al. Serevent Nationwide Surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids. Pharmaceuticals 2010;3:514-40
   Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362(13):1169-71
   PubMed Web of Science ®Google Scholar
• Shaw RJ. Inhaled corticosteroids for adult asthma: impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety. Respir Med 1999;93:149-60
   PubMed Web of Science ®Google Scholar
• Postma DS, Kerstjens HAM, ten Hacken NHT. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn-Schmiedeberg’s Arch Pharmacol 2008;378:203-15
   Google Scholar
• Derendorf H. Corticosteroid pharmacokinetic/pharmacodynamics parameters and their relationship to safety and efficacy. Allergy Asthma Proc 2005;26(5):327-35
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Hubbell J, Cutler DL, et al. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler. Chest 2013;144(6):1795-802
   PubMed Web of Science ®Google Scholar
• Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007;62(10):1182-8
   PubMed Web of Science ®Google Scholar
• Smyth HDC. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv 2005;2(1):53-74
   Google Scholar
• Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin Drug Deliv 2007;4(3):215-34
   PubMed Web of Science ®Google Scholar
• Longest PW, Tian G, Son YJ, et al. Engineered drug targeting to the lungs: ensuring growth and deposition of submicrometer aerosols through device design and formulations. Respir Drug Deliv 2012;1:61-72
   Google Scholar
• Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 2005;50:1201-8
   PubMedGoogle Scholar
• Malhotra G, Rote K, Gogtay J. Integrated dose counters: technical aspects and functional specifications. In: Dalby RN, Byron PR, Peart J, Farr SJ, Suman JD, Young PM, Traini D, editors. Respiratory drug delivery 2014. Volume 2 DHI Publishing; River Grove, IL: 2014. p. 397-400
   Google Scholar
• Aggarwal B, Gogtay J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. Expert Rev Respir Med 2014;8(3):349-56
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT00449046. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00449046
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01795664. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01795664
   Google Scholar
• ClinicalTrials.gov Identifier: NCT00404261. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00404261
   Google Scholar
• ClinicalTrials.gov Identifier: NCT02113436. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02113436
   Google Scholar
• ClinicalTrials.gov Identifier: NCT00369993. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00369993
   Google Scholar
• ClinicalTrials.gov Identifier: NCT00867737. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00867737
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01332422. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01332422
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01225913. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01225913
   Google Scholar
• ClinicalTrials.gov Identifier: NCT00576069. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00576069
   Google Scholar